Data from epidemiologic studies show that among persons of age ∅65 years, 20–30% of all hospitalizations and deaths due to peptic ulcer disease were attributable to therapy with NSAIDs.[10–12] More recently, cyclooxygenase-2 (COX-2) inhibitors like celecoxib and rofecoxib have been shown to be more effective and have lesser side effects on GI system than NSAIDs.[13,14] However, COX-2-specific inhibitors can cause renal toxicity. This evidence concerns the gene PTGS2 and peptic ulcer disease.